Equity offerings played a big role for two of these companies.
News & Analysis: Advaxis
These stocks jumped on a strong start to the second quarter.
The small-cap biotech reported encouraging news about its prostate cancer therapy.
Despite a lack of particularly damaging news, investors are losing patience with this biotech.
A new collaboration with Amgen, Inc. is sparking investor optimism for a second consecutive day.
The moody market wasn't kind to Advaxis last month. Here's why.
Despite an uneventful month, Advaxis shares rose on some bargain shopping.
Advaxis' pipeline takes baby steps forward in April, but still remains a risky bet.
A positive trial in canines with bone cancer could have implications for human cancer patients, too.
Advaxis' stock pushed higher in 2015 because of the market's growing excitement for the emerging field of cancer immunotherapy.